CA2238815A1 - Composition servant a traiter la douleur - Google Patents

Composition servant a traiter la douleur Download PDF

Info

Publication number
CA2238815A1
CA2238815A1 CA002238815A CA2238815A CA2238815A1 CA 2238815 A1 CA2238815 A1 CA 2238815A1 CA 002238815 A CA002238815 A CA 002238815A CA 2238815 A CA2238815 A CA 2238815A CA 2238815 A1 CA2238815 A1 CA 2238815A1
Authority
CA
Canada
Prior art keywords
carbon atoms
alkyl
alkoxy
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002238815A
Other languages
English (en)
Inventor
Charles Howard Mitch
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2238815A1 publication Critical patent/CA2238815A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition et un procédé servant à traiter la douleur au moyen d'une composition contenant des composés muscariniques sélectionnés et un ou plusieurs composés sélectionnés dans le groupe constitué par des médicaments anti-inflammatoires non stéroïdiens, des acétaminophènes, des opioïdes et des composés alpha-adrenergiques.
CA002238815A 1995-12-07 1996-12-05 Composition servant a traiter la douleur Abandoned CA2238815A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US829995P 1995-12-07 1995-12-07
US60/008,299 1995-12-07

Publications (1)

Publication Number Publication Date
CA2238815A1 true CA2238815A1 (fr) 1997-06-12

Family

ID=21730869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002238815A Abandoned CA2238815A1 (fr) 1995-12-07 1996-12-05 Composition servant a traiter la douleur

Country Status (13)

Country Link
EP (1) EP0871445A4 (fr)
JP (1) JP2000501709A (fr)
KR (1) KR19990071976A (fr)
CN (1) CN1208349A (fr)
AU (1) AU705031B2 (fr)
CA (1) CA2238815A1 (fr)
CZ (1) CZ174698A3 (fr)
EA (1) EA199800533A1 (fr)
IL (1) IL124419A0 (fr)
NO (1) NO982562L (fr)
NZ (1) NZ324988A (fr)
PL (1) PL327137A1 (fr)
WO (1) WO1997020561A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046227A1 (fr) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition analgesique
AU5123200A (en) 1999-06-04 2000-12-28 Eli Lilly And Company 7-oxo-2-azabicyclo(2.2.1)heptanes as selective muscarinic receptor antagonist
CA2919892C (fr) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Comprime extrude anti-abus a liberation immediate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (fr) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus à libération immédiate
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) * 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5260293A (en) * 1988-01-30 1993-11-09 Merck Sharp & Dohme Limited Pyrazines, pyrimidines and pyridazines useful in the treatment of senile dementia
IL89351A0 (en) * 1988-03-14 1989-09-10 Lundbeck & Co As H 4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridines,process for their preparation and pharmaceutical compositions containing them
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
CA2185805A1 (fr) * 1994-03-18 1995-09-28 Georg Frank Cetoprofene a faible dosage

Also Published As

Publication number Publication date
PL327137A1 (en) 1998-11-23
NZ324988A (en) 1999-08-30
EA199800533A1 (ru) 1999-02-25
WO1997020561A1 (fr) 1997-06-12
AU705031B2 (en) 1999-05-13
NO982562D0 (no) 1998-06-04
NO982562L (no) 1998-07-10
AU1279197A (en) 1997-06-27
EP0871445A4 (fr) 2001-01-10
CZ174698A3 (cs) 1998-10-14
JP2000501709A (ja) 2000-02-15
IL124419A0 (en) 1998-12-06
CN1208349A (zh) 1999-02-17
KR19990071976A (ko) 1999-09-27
EP0871445A1 (fr) 1998-10-21

Similar Documents

Publication Publication Date Title
Freitas et al. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model
SK13952002A3 (sk) Farmaceutická kompozícia na liečenie akútnej, chronickej a/alebo neuropatickej bolesti a migrén
JP6419294B2 (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
CA2238815A1 (fr) Composition servant a traiter la douleur
AU715645B2 (en) Method for treating pain
WO1997020556A9 (fr) Methode de traitement de la douleur
RU2419433C2 (ru) Средство для профилактики или лечения алкогольной зависимости и зависимости от лекарственных веществ
WO1998046227A1 (fr) Composition analgesique
US5574029A (en) Method for treating anxiety
US20090012101A1 (en) Mucarinic Agonists and Methods of Use Thereof
WO1998046601A1 (fr) Composition pour le traitement de la douleur
MXPA98004519A (en) Composition to treat do
WO2008118326A1 (fr) Agonistes muscariniques et procédés d'utilisation de ceux-ci
Toma et al. Neuronal nicotinic acetylcholine receptor agonists
WO2009140483A1 (fr) Agonistes muscariniques servant de stimulateurs cognitifs

Legal Events

Date Code Title Description
FZDE Discontinued